PMC:7205724 / 21785-21983
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
740 | 16-20 | Gene | denotes | ACE2 | Gene:59272 |
750 | 99-102 | Gene | denotes | IL6 | Gene:3569 |
751 | 117-135 | Disease | denotes | hyper inflammation | MESH:D007249 |
762 | 136-147 | Chemical | denotes | Tocilizumab | MESH:C502936 |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T159 | 55-64 | Body_part | denotes | cytokines | http://purl.org/sig/ont/fma/fma84050 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T164 | 123-135 | Disease | denotes | inflammation | http://purl.obolibrary.org/obo/MONDO_0021166 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T260 | 85-86 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T261 | 177-178 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T262 | 179-188 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | humanized |
LitCovid-sample-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T176 | 23-64 | Sentence | denotes | 6.2 Targeting pro-inflammatory cytokines |
T177 | 66-84 | Sentence | denotes | 6.2.1 Hypothesis: |
T178 | 85-135 | Sentence | denotes | A mAb against IL6 can attenuate hyper inflammation |
LitCovid-sample-Pubtator
Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
---|---|---|---|---|---|
740 | 16-20 | Gene | denotes | ACE2 | Gene:59272 |
750 | 99-102 | Gene | denotes | IL6 | Gene:3569 |
751 | 117-135 | Disease | denotes | hyper inflammation | MESH:D007249 |
762 | 136-147 | Chemical | denotes | Tocilizumab | MESH:C502936 |
LitCovid-sample-UniProt
Id | Subject | Object | Predicate | Lexical cue | uniprot_id |
---|---|---|---|---|---|
T2073 | 99-102 | Protein | denotes | IL6 | https://www.uniprot.org/uniprot/Q9XT80|https://www.uniprot.org/uniprot/Q9UCU4|https://www.uniprot.org/uniprot/Q9UCU3|https://www.uniprot.org/uniprot/Q9UCU2|https://www.uniprot.org/uniprot/Q9MZR1|https://www.uniprot.org/uniprot/Q9MYZ7|https://www.uniprot.org/uniprot/Q95KN6|https://www.uniprot.org/uniprot/Q95181|https://www.uniprot.org/uniprot/Q90YI0|https://www.uniprot.org/uniprot/Q8MKH0|https://www.uniprot.org/uniprot/Q8BN26|https://www.uniprot.org/uniprot/Q865X6|https://www.uniprot.org/uniprot/Q865W7|https://www.uniprot.org/uniprot/Q6V919|https://www.uniprot.org/uniprot/Q6L6X6|https://www.uniprot.org/uniprot/Q5I6E3|https://www.uniprot.org/uniprot/Q3UCQ0|https://www.uniprot.org/uniprot/Q2MH06|https://www.uniprot.org/uniprot/Q28819|https://www.uniprot.org/uniprot/Q28747|https://www.uniprot.org/uniprot/Q28319|https://www.uniprot.org/uniprot/Q25BC2|https://www.uniprot.org/uniprot/Q0PW36|https://www.uniprot.org/uniprot/Q0GGL7|https://www.uniprot.org/uniprot/Q08DT2|https://www.uniprot.org/uniprot/P79341|https://www.uniprot.org/uniprot/P51494|https://www.uniprot.org/uniprot/P46650|https://www.uniprot.org/uniprot/P41693|https://www.uniprot.org/uniprot/P41683|https://www.uniprot.org/uniprot/P41323|https://www.uniprot.org/uniprot/P29455|https://www.uniprot.org/uniprot/P26893|https://www.uniprot.org/uniprot/P26892|https://www.uniprot.org/uniprot/P20607|https://www.uniprot.org/uniprot/P08505|https://www.uniprot.org/uniprot/P05231|https://www.uniprot.org/uniprot/O46568|https://www.uniprot.org/uniprot/O35736|https://www.uniprot.org/uniprot/O19007|https://www.uniprot.org/uniprot/B6CKP4|https://www.uniprot.org/uniprot/A9QWQ9|https://www.uniprot.org/uniprot/A3FBE9|https://www.uniprot.org/uniprot/A0S0B0 |
LitCovid-sample-Enju
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T37015 | 1-4 | IN | denotes | for |
T86465 | 5-12 | VBG | denotes | binding |
T1893 | 13-15 | TO | denotes | to |
T91196 | 16-20 | NN | denotes | ACE2 |
T54390 | 23-26 | CD | denotes | 6.2 |
T7377 | 28-37 | VBG | denotes | Targeting |
T2754 | 38-54 | JJ | denotes | pro-inflammatory |
T79617 | 55-64 | NNS | denotes | cytokines |
T42975 | 66-71 | CD | denotes | 6.2.1 |
T96891 | 73-83 | NN | denotes | Hypothesis |
T41163 | 83-84 | -COLON- | denotes | : |
T35174 | 85-86 | DT | denotes | A |
T74401 | 87-90 | NN | denotes | mAb |
T75556 | 91-98 | IN | denotes | against |
T83617 | 99-102 | NN | denotes | IL6 |
T67953 | 103-106 | MD | denotes | can |
T68840 | 107-116 | VB | denotes | attenuate |
T2426 | 117-122 | NN | denotes | hyper |
T92661 | 123-135 | NN | denotes | inflammation |
T86439 | 136-147 | NNP | denotes | Tocilizumab |
T21494 | 147-148 | -COMMA- | denotes | , |
T50157 | 149-153 | RB | denotes | also |
T26283 | 154-159 | VBN | denotes | known |
T43571 | 160-162 | IN | denotes | as |
T44785 | 163-172 | NN | denotes | atlizumab |
T96810 | 172-173 | -COMMA- | denotes | , |
T58761 | 174-176 | VBZ | denotes | is |
T56416 | 177-178 | DT | denotes | a |
T79548 | 179-188 | JJ | denotes | humanized |
R67300 | T86465 | T37015 | arg2Of | binding,for |
R53767 | T86465 | T1893 | arg1Of | binding,to |
R3636 | T91196 | T1893 | arg2Of | ACE2,to |
R75716 | T54390 | T7377 | arg1Of | 6.2,Targeting |
R93465 | T79617 | T7377 | arg2Of | cytokines,Targeting |
R69719 | T79617 | T2754 | arg1Of | cytokines,pro-inflammatory |
R92270 | T96891 | T42975 | arg1Of | Hypothesis,6.2.1 |
R64820 | T96891 | T41163 | arg1Of | Hypothesis,: |
R32577 | T74401 | T41163 | arg2Of | mAb,: |
R79527 | T74401 | T35174 | arg1Of | mAb,A |
R58839 | T74401 | T75556 | arg1Of | mAb,against |
R72696 | T83617 | T75556 | arg2Of | IL6,against |
R84073 | T96891 | T67953 | arg1Of | Hypothesis,can |
R74784 | T68840 | T67953 | arg2Of | attenuate,can |
R14765 | T96891 | T68840 | arg1Of | Hypothesis,attenuate |
R94556 | T92661 | T68840 | arg2Of | inflammation,attenuate |
R98822 | T92661 | T2426 | arg1Of | inflammation,hyper |
R83125 | T86439 | T21494 | arg1Of | Tocilizumab,"," |
R13146 | T26283 | T50157 | arg1Of | known,also |
R82868 | T86439 | T26283 | arg2Of | Tocilizumab,known |
R76811 | T26283 | T43571 | arg1Of | known,as |
R6462 | T44785 | T43571 | arg2Of | atlizumab,as |
R65301 | T58761 | T96810 | arg1Of | is,"," |
R91756 | T86439 | T58761 | arg1Of | Tocilizumab,is |
LitCovid-sample-PD-GO-BP-0
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T31 | 123-135 | http://purl.obolibrary.org/obo/GO_0006954 | denotes | inflammation |
LitCovid-sample-PD-FMA
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T159 | 55-64 | Body_part | denotes | cytokines | http://purl.org/sig/ont/fma/fma84050 |
LitCovid-sample-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T159 | 123-135 | Disease | denotes | inflammation | http://purl.obolibrary.org/obo/MONDO_0021166 |
LitCovid-sample-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T27 | 123-135 | http://purl.obolibrary.org/obo/GO_0006954 | denotes | inflammation |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T27 | 123-135 | http://purl.obolibrary.org/obo/GO_0006954 | denotes | inflammation |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T176 | 23-64 | Sentence | denotes | 6.2 Targeting pro-inflammatory cytokines |
T177 | 66-84 | Sentence | denotes | 6.2.1 Hypothesis: |
T178 | 85-135 | Sentence | denotes | A mAb against IL6 can attenuate hyper inflammation |